Molecular targeted therapy has recently become a focus of study for non-small cell lung cancer.The drugs for molecular targeted therapy mainly include monoclonal antibodies against the epidermal growth factor receptor (EGFR), against vascular endothelial growth factor receptor（VEGFR）, and EGFR tyrosine kinase inhibitors.These drugs have achieved positive outcomes in clinic, but they also have toxic effects such as rash, diarrhea, and hypertension.Some new agents in clinical development, such as sorafenib, sunitinib, vorinostat, vandetanib, also showed toxic effects, which greatly influence the patients quality of life and reduce the compliance for the drugs.This paper reviews the toxicities and the managements of molecular targeted drugs during treatment of non-small cell lung cancer.